Randomised , open-label , crossover trial of DR-HC or thrice-daily hydrocortisone for @ months each ( stage @ ) followed by two consecutive , prospective , open-label studies of DR-HC for @ months ( stage @ ) and @ months ( stage @ ) at five university clinics in Sweden .